- Open Access
Optimization of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection
Biological Procedures Online volume 5, pages 43–52 (2003)
Type I interferon (IFN) gene therapy modulates the immune response leading to inflammatory heart disease following cytomegalovirus (CMV) infection in a murine model of post-viral myocarditis. Efficacy of different immunisation protocols for the IFN constructs was influenced by the dose of DNA, subtype choice, combination use, pre-medication, and timing of DNA administration. Optimal efficacy was found with bupivacaine treatment prior to DNA inoculation of 200µgIFN DNA 14 days prior to virus challenge. Maximal antiviral and antimyocarditic effects were achieved with this vaccination schedule. Furthermore, inoculation of synergistic IFN subtypes demonstrated enhanced efficacy when delivered either alone or with CMVgB DNA vaccination in the CMV model. Thus naked DNA delivery of IFN provides an avenue of immunotherapy for regulating herpesvirus-induced diseases.
Gherardi MM, Ramirez JC, Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 Env antigen in a DNA prime/ vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide.J Virol 2000; 74:6278–6286.
Noormohammadi AH, Hochrein H, Curtis JM, Baldwin TM, Handman E. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen.Vaccine 2001; 19:4043–4052.
Prud’homme GJ, Lawson BR, Chang Y, Theofilopoulos AN. Immunotherapeutic gene transfer into muscle.Trends Immunol 2001; 22:149–155.
Min W, Lillehoj HA, Burnside J, Weining KC, Staeheli P, Zhu JJ. Adjuvant effects ofIL-1β, IL-2, IL-8, IL-15, IFNα, IFNγ, TGFβ4 andlymphotactin on DNA vaccination againstEimeria acervulina.Vaccine 2002; 20:267–274.
Bartlett EJ, Cull VS, Brekalo NL, Lenzo JC, James CM. Synergy of type I interferon-A6 and interferon-B naked DNA immunotherapy for cytomegalovirus infections.Immunol Cell Biol 2002; 80:425–435.
Lawson CM, Yeow WS, Lee CM, Beilharz MW.In vivo expression of an interferon-α gene by intramuscular injection of naked DNA.J Interferon Cytokine Res 1997; 17:255–261.
Yeow WS, Lawson CM, Beilharz MW. Antiviral activities of interferon-α subtypesin vivo.J Immunol 1998; 160:2932–2939.
Cull VS, Bartlett EJ, James CM. Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.Immunol 2002; 106:428–437.
Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James CM. Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice.Gene Therapy 2002; 9:1369–1378.
Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α.Proc Nat Acad Sci USA 1999; 96:1553–1558.
Noisakran S, Campbell IL, Carr DJJ. Ectopic expression of DNA encoding IFN-α1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis.J Immunol 1999;162:4184–4190.
Danko I, Wolff JA. Direct Gene Transfer into Muscle.Vaccine 1994; 12:1499–1502.
Kusakabe K, Xin K, Katoh H, Sumino K, Hagiwara E, Kawamoto S, Okuda K, Miyagi Y, Aoki I, Nishioka K, Klinman D, Okuda K. The timing of GM-CSF expression plasmid administration influences the Th1/ Th2 response induced by an HIV-1-specific DNA vaccine.J Immunol 2000; 164:3102–3111.
Moelling K. DNA for genetic vaccination and therapy.Cytokines, Cell Molec Therapy 1997; 3:127–136.
Prud’homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-γ receptor/ IgG1 fusion protein.Gene Therapy 1999; 6:771–777.
Chang Y, Prud’homme GJ. Intramuscular administration of expression plasmids encoding interferon-γ-receptor/ IgG1 or IL-4/ IgG1 chimeric proteins protects from autoimmunity.J Gene Med 1999; 1:415–423.
Vitadello M, Schiaffino MV, Picard A, Scarpa M, Schiaffino S. Gene transfer in regenerating muscle.Human Gene Therapy 1994; 5:11–18.
Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-α/β), in innate and adaptive immune responses to viral infections.Sem Immunol 1998;10:383–390.
Marié I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-α genes by positive feedback through interferon regulatory factor-7.EMBO J 1998; 17:6660–6669.
Lenzo JC, Fairweather D, Cull V, Shellam GR, James (Lawson) CM. Characterisation of murine cytomegalovirus myocarditis: cellular infiltration of the heart and virus persistence.J Mol Cell Cardiol 2002; 34:629–640.
Ulmer JB. Influenza DNA vaccines.Vaccine 2002; 20:S74–76.
MacGregor RR, Ginsberg R, Ugen KE, Baine Y, Kang CU, Tu XM, Higgins T, Weiner DB, Boyer JD. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev.AIDS 2002; 16:2137–2143.
Published: February 17, 2003
About this article
Cite this article
Bartlett, E.J., Cull, V.S., Mowe, E.N. et al. Optimization of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection. Biol. Proced. Online 5, 43–52 (2003). https://doi.org/10.1251/bpo45
- gene therapy